Serkan Celik, Linus Bodeström Eriksson, Jakob Hytting, Annette Waldemar, Panagiotis Mallios, Amanda Berggren, Ellen Oscarsson, Christofer Digerfeldt, Magnus Wijkman, Laila Hubbert
{"title":"肌钙蛋白- t作为急诊科房颤患者死亡率的预测因子","authors":"Serkan Celik, Linus Bodeström Eriksson, Jakob Hytting, Annette Waldemar, Panagiotis Mallios, Amanda Berggren, Ellen Oscarsson, Christofer Digerfeldt, Magnus Wijkman, Laila Hubbert","doi":"10.1186/s12872-024-04388-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>High-sensitive Troponin-T (hsTnT) is often increased in acute illness and may be of prognostic importance in patients with atrial fibrillation (AF). The aim of this study was to analyse the characteristics and data of patients attending the emergency department (ED) with AF to determine whether age-adjusted hsTnT levels can predict mortality.</p><p><strong>Methods: </strong>This retrospective, single centre, register-based cohort study included all patients ≥ 18 years attending the emergency department during 2018 and 2020 with a primary diagnosis at the ED of AF and sampled for hsTnT. Symptoms, comorbidities, lab results, and characteristics were registered. Patients were divided into groups based on hsTnT level (< 15, 15-50, and > 50 ng/L).</p><p><strong>Primary outcomes: </strong>30-day and 1-year mortality.</p><p><strong>Results: </strong>A total of 625 patients were included (median age 72, and 45% female). All-cause mortality was 2% at 30 days and 8% at 1-year. The hazard ratio (HR) for 30-day mortality was 4.17 (95% confidence interval (CI) 0.49-35.79, p = 0.192) for hsTnT 15-50 ng/L and 9.64 (95% CI 0.98-95.30, p = 0.053) for hsTnT > 50 ng/L compared to hsTnT < 15 ng/L when adjusted for age. The HR for 1-year mortality was 4.82 (95% CI 1.81-12.82, p = 0.002) for hsTnT 15-50 ng/L and 9.70 (95% CI 3.27-28.74, p < 0.001) for hsTnT > 50 ng/L compared to hsTnT < 15 ng/L when adjusted for age.</p><p><strong>Conclusions: </strong>Elevated hsTnT levels increase the risk for 30-day and 1-year mortality independently of age. Both mild and major elevation of hsTnT levels is associated with increased risk for 1-year mortality regardless of age.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"24 1","pages":"719"},"PeriodicalIF":2.0000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660876/pdf/","citationCount":"0","resultStr":"{\"title\":\"Troponin-T as predictor of mortality in patients attending the emergency department with atrial fibrillation.\",\"authors\":\"Serkan Celik, Linus Bodeström Eriksson, Jakob Hytting, Annette Waldemar, Panagiotis Mallios, Amanda Berggren, Ellen Oscarsson, Christofer Digerfeldt, Magnus Wijkman, Laila Hubbert\",\"doi\":\"10.1186/s12872-024-04388-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>High-sensitive Troponin-T (hsTnT) is often increased in acute illness and may be of prognostic importance in patients with atrial fibrillation (AF). The aim of this study was to analyse the characteristics and data of patients attending the emergency department (ED) with AF to determine whether age-adjusted hsTnT levels can predict mortality.</p><p><strong>Methods: </strong>This retrospective, single centre, register-based cohort study included all patients ≥ 18 years attending the emergency department during 2018 and 2020 with a primary diagnosis at the ED of AF and sampled for hsTnT. Symptoms, comorbidities, lab results, and characteristics were registered. Patients were divided into groups based on hsTnT level (< 15, 15-50, and > 50 ng/L).</p><p><strong>Primary outcomes: </strong>30-day and 1-year mortality.</p><p><strong>Results: </strong>A total of 625 patients were included (median age 72, and 45% female). All-cause mortality was 2% at 30 days and 8% at 1-year. The hazard ratio (HR) for 30-day mortality was 4.17 (95% confidence interval (CI) 0.49-35.79, p = 0.192) for hsTnT 15-50 ng/L and 9.64 (95% CI 0.98-95.30, p = 0.053) for hsTnT > 50 ng/L compared to hsTnT < 15 ng/L when adjusted for age. The HR for 1-year mortality was 4.82 (95% CI 1.81-12.82, p = 0.002) for hsTnT 15-50 ng/L and 9.70 (95% CI 3.27-28.74, p < 0.001) for hsTnT > 50 ng/L compared to hsTnT < 15 ng/L when adjusted for age.</p><p><strong>Conclusions: </strong>Elevated hsTnT levels increase the risk for 30-day and 1-year mortality independently of age. Both mild and major elevation of hsTnT levels is associated with increased risk for 1-year mortality regardless of age.</p>\",\"PeriodicalId\":9195,\"journal\":{\"name\":\"BMC Cardiovascular Disorders\",\"volume\":\"24 1\",\"pages\":\"719\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-12-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660876/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Cardiovascular Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12872-024-04388-8\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cardiovascular Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12872-024-04388-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
背景:高敏感性肌钙蛋白- t (hsTnT)在急性疾病中经常升高,可能对房颤(AF)患者的预后具有重要意义。本研究的目的是分析急诊科(ED)房颤患者的特征和数据,以确定年龄调整后的hsTnT水平是否可以预测死亡率。方法:这项回顾性、单中心、基于登记的队列研究纳入了2018年至2020年期间在急诊科就诊的所有≥18岁的患者,这些患者最初诊断为房颤的急诊科,并取样为hsTnT。记录了症状、合并症、实验室结果和特征。根据hsTnT水平(50 ng/L)进行分组。主要结局:30天和1年死亡率。结果:共纳入625例患者(中位年龄72岁,其中45%为女性)。30天全因死亡率为2%,1年死亡率为8%。hsTnT 15-50 ng/L患者30天死亡率的风险比(HR)为4.17(95%可信区间(CI) 0.49-35.79, p = 0.192), hsTnT 50 ng/L患者30天死亡率的风险比(HR)为9.64 (95% CI 0.98-95.30, p = 0.053)。结论:hsTnT水平升高会增加30天和1年死亡率的风险,与年龄无关。不论年龄大小,hsTnT水平的轻度和重度升高均与1年死亡风险增加相关。
Troponin-T as predictor of mortality in patients attending the emergency department with atrial fibrillation.
Background: High-sensitive Troponin-T (hsTnT) is often increased in acute illness and may be of prognostic importance in patients with atrial fibrillation (AF). The aim of this study was to analyse the characteristics and data of patients attending the emergency department (ED) with AF to determine whether age-adjusted hsTnT levels can predict mortality.
Methods: This retrospective, single centre, register-based cohort study included all patients ≥ 18 years attending the emergency department during 2018 and 2020 with a primary diagnosis at the ED of AF and sampled for hsTnT. Symptoms, comorbidities, lab results, and characteristics were registered. Patients were divided into groups based on hsTnT level (< 15, 15-50, and > 50 ng/L).
Primary outcomes: 30-day and 1-year mortality.
Results: A total of 625 patients were included (median age 72, and 45% female). All-cause mortality was 2% at 30 days and 8% at 1-year. The hazard ratio (HR) for 30-day mortality was 4.17 (95% confidence interval (CI) 0.49-35.79, p = 0.192) for hsTnT 15-50 ng/L and 9.64 (95% CI 0.98-95.30, p = 0.053) for hsTnT > 50 ng/L compared to hsTnT < 15 ng/L when adjusted for age. The HR for 1-year mortality was 4.82 (95% CI 1.81-12.82, p = 0.002) for hsTnT 15-50 ng/L and 9.70 (95% CI 3.27-28.74, p < 0.001) for hsTnT > 50 ng/L compared to hsTnT < 15 ng/L when adjusted for age.
Conclusions: Elevated hsTnT levels increase the risk for 30-day and 1-year mortality independently of age. Both mild and major elevation of hsTnT levels is associated with increased risk for 1-year mortality regardless of age.
期刊介绍:
BMC Cardiovascular Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of disorders of the heart and circulatory system, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology, and controlled trials.